All In MedTech

FDA Clearance Tracker · P950014-S021

PROSTATRON (TM) SYSTEM DISPOSABLE TREATMENT APPLICATOR

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 19, 2001 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 19, 2001

Approved

Time to decision

79 days

Received Jul 2, 2001. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P950014-S021
Device name
PROSTATRON (TM) SYSTEM DISPOSABLE TREATMENT APPLICATOR
Applicant location
Plymouth, MN
Received
Jul 2, 2001
Decided
Sep 19, 2001
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P950014

Device type

Device class
Class III

Every decision under product code MEQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A NEW MANUFACTURING SITE LOCATED AT VENUSA DE MEXICO S.A. DE C.V, CHIHUAHUA, MEXICO, IN WHICH THE PROSTATRON DISPOSABLE TREATMENT APPLICATOR WILL BE ASSEMBLED. IN ADDITION, APPROVAL FOR A MANUFACTURING FACILITY LOCATED AT VENUSA LTD., EL PASO, TEXAS, FOR THE RECEIPT, INSPECTION, STORAGE, AND RELEASE OF COMPONENTS AND THE QUARANTINE OF FINISHED STERILIZED DEVICES. ALSO, THE APPLICATOR WILL BE STERILIZED AT GRIFFITH MICROSCIENCE, SANTA TERESA, NEW MEXICO.

Source documents

Other decisions for Urologix, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.